Cullinan Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
CGEM$11.23-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity
(in thousands, except share amounts)
| Preferred Stock · Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · NoncontrollingInterests in · TotalStockholders’ | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Income (Loss) | Deficit | Subsidiaries | Equity | |
| Balances at December 31, 2023 | 647,500 | $— | 42,900,083 | $4 | $654,685 | $(129) | $(200,857) | $192 | $453,895 |
| Issuance of common stock and pre-funded warrants, net of issuance costs | — | — | 14,421,070 | 1 | 262,651 | — | — | — | 262,652 |
| Issuance of common stock under equity-based compensation plans | — | — | 1,189,457 | 1 | 7,983 | — | — | — | 7,984 |
| Equity-based compensation | — | — | — | — | 37,824 | — | — | — | 37,824 |
| Acquisition of noncontrolling interests | — | — | — | — | (4,448) | — | — | — | (4,448) |
| Unrealized loss on investments | — | — | — | — | — | (4) | — | — | (4) |
| Net loss | — | — | — | — | — | — | (167,383) | (192) | (167,575) |
| Balances at December 31, 2024 | 647,500 | — | 58,510,610 | 6 | 958,695 | (133) | (368,240) | — | 590,328 |
| Issuance of common stock upon conversion of preferred stock | (91,565) | — | 915,650 | — | — | — | — | — | — |
| Issuance of common stock under equity-based compensation plans | — | — | 502,128 | — | 1,088 | — | — | — | 1,088 |
| Issuance of common stock upon exercise of pre-funded warrants | — | — | 315,748 | — | — | — | — | — | — |
| Equity-based compensation | — | — | — | — | 36,040 | — | — | — | 36,040 |
| Unrealized gain on investments | — | — | — | — | — | 1,153 | — | — | 1,153 |
| Net loss | — | — | — | — | — | — | (219,879) | — | (219,879) |
| Balances at December 31, 2025 | 555,935 | $— | 60,244,136 | $6 | $995,823 | $1,020 | $(588,119) | $— | $408,730 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.